Table 4.
Absorbed doses per unit administered activity. Due to the uncertainties of quantification in SPECT/CT at low activity levels, the ratios differ from those shown in Table 2
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Gy per GBq [177Lu]Lu-DOTA-TOC | |||||
| Kidneys | 0.75 | 1.58 | 0.42 | 0.67 | 1.70 |
| Tumours | 2.14 | 0.46 | 0.64 | 5.65 | 4.02 |
| Spleen | 0.20 | 3.06 | 0.27 | 0.24 | 0.39 |
| Liver | 0.17 | 0.49 | 0.11 | 0.06 | |
| Gy per GBq [177Lu]Lu-DOTA-EB-TATE | |||||
| Kidneys | 2.63 | 4.11 | 3.79 | 3.73 | 2.45 |
| Tumours | 4.21 | 1.45 | 1.17 | 4.35 | 6.64 |
| Spleen | 1.04 | 3.85 | 1.66 | 1.25 | 1.10 |
| Liver | 0.60 | 0.39 | 0.49 | 0.28 | |
The liver of Patient 5 was not evaluable due to hepatic metastasis